SciClone Pharmaceuticals (Holdings) (HKSE:06600) Cash per Share : HK$3.88 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). SciClone Pharmaceuticals (Holdings)'s Cash per Share for the quarter that ended in Dec. 2023 was HK$3.88.

SciClone Pharmaceuticals (Holdings) Cash per Share Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Cash per Share Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

1.71

2.08

4.06

4.25

3.88

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash per Share	Get a 7-Day Free Trial						4.06	4.51	4.25	4.15	3.88

SciClone Pharmaceuticals (Holdings) Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

SciClone Pharmaceuticals (Holdings)'s Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2431.788	/	627
	=	3.88

SciClone Pharmaceuticals (Holdings)'s Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2431.788	/	627
	=	3.88

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

SciClone Pharmaceuticals (Holdings) Cash per Share Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Cash per Share

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines